Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy
作者： G. Messalli , M. Imbriaco , G. Avitabile , R. Russo , D. Iodice
DOI: 10.1007/S11547-011-0710-9
关键词:
摘要: Purpose Anderson-Fabry disease is a multisystemic disorder of lipid metabolism secondary to X-chromosome alterations and frequently associated with cardiac manifestations such as left ventricular (LV) hypertrophy, gradually leading an alteration in performance. The purpose this study was monitor, using magnetic resonance imaging (MRI), any changes produced by enzyme replacement therapy agalsidase beta at the level patients Anderson-Fabry disease.
springer.com
elsevier.com
researchgate.net 
sci-hub.se 参考文章(28)
L Spinelli, A Pisani, M Sabbatini, M Petretta, MV Andreucci, D Procaccini, N Lo Surdo, S Federico, B Cianciaruso, Enzyme replacement therapy with agalsidase β improves cardiac involvement in Fabry's disease Clinical Genetics. ,vol. 66, pp. 158- 165 ,(2004) , 10.1111/J.1399-0004.2004.00284.X
Anette T Møller, Troels S Jensen, Neurological manifestations in Fabry's disease. Nature Reviews Neurology. ,vol. 3, pp. 95- 106 ,(2007) , 10.1038/NCPNEURO0407
Charles B. Higgins, Robert Herfkens, Martin J. Lipton, Richard Sievers, Philip Sheldon, Leon Kaufman, Lawrence E. Crooks, Nuclear Magnetic Resonance Imaging of Acute Myocardial Infarction in Dogs: Alterations in Magnetic Relaxation Times American Journal of Cardiology. ,vol. 52, pp. 184- 188 ,(1983) , 10.1016/0002-9149(83)90093-0
Meinrad Beer, Frank Weidemann, Frank Breunig, Anita Knoll, Sabrina Koeppe, Wolfram Machann, Dietbert Hahn, Christoph Wanner, Jörg Strotmann, Jörn Sandstede, Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. American Journal of Cardiology. ,vol. 97, pp. 1515- 1518 ,(2006) , 10.1016/J.AMJCARD.2005.11.087
A. Linhart, P. M Elliott, The heart in Anderson-Fabry disease and other lysosomal storage disorders Heart. ,vol. 93, pp. 528- 535 ,(2007) , 10.1136/HRT.2005.063818
Raphael Schiffmann, Jeffrey B. Kopp, Howard A. Austin III, Sharda Sabnis, David F. Moore, Thais Weibel, James E. Balow, Roscoe O. Brady, Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. ,vol. 285, pp. 2743- 2749 ,(2001) , 10.1001/JAMA.285.21.2743
Francesco De Cobelli, Antonio Esposito, Elena Belloni, Maurizio Pieroni, Gianluca Perseghin, Cristina Chimenti, Andrea Frustaci, Alessandro Del Maschio, Delayed-Enhanced Cardiac MRI for Differentiation of Fabry's Disease from Symmetric Hypertrophic Cardiomyopathy American Journal of Roentgenology. ,vol. 192, ,(2009) , 10.2214/AJR.08.1201
Dominique P. Germain, Stephen Waldek, Maryam Banikazemi, David A. Bushinsky, Joel Charrow, Robert J. Desnick, Philip Lee, Thomas Loew, Anouk C. Vedder, Rekha Abichandani, William R. Wilcox, Nathalie Guffon, Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase β Therapy in Patients with Fabry Disease Journal of The American Society of Nephrology. ,vol. 18, pp. 1547- 1557 ,(2007) , 10.1681/ASN.2006080816
Robert J Desnick, Roscoe Brady, John Barranger, Allan J Collins, Dominique P Germain, Martin Goldman, Gregory Grabowski, Seymour Packman, William R Wilcox, Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Annals of Internal Medicine. ,vol. 138, pp. 338- 346 ,(2003) , 10.7326/0003-4819-138-4-200302180-00014
Robert J Hopkin, John Bissler, Maryam Banikazemi, Lorne Clarke, Christine M Eng, Dominique P Germain, Roberta Lemay, Anna Tylki-Szymanska, William R Wilcox, Characterization of Fabry Disease in 352 Pediatric Patients in the Fabry Registry Pediatric Research. ,vol. 64, pp. 550- 555 ,(2008) , 10.1203/PDR.0B013E318183F132